CGT Global News

Featured Post

CGT Global Appoints Charlotte Ivancic to Board of Advisors, Strengthening Strategic Leadership in Cell and Gene Therapy Policy and Market Access

By camerontucker | May 21, 2026 | Comments Off on CGT Global Appoints Charlotte Ivancic to Board of Advisors, Strengthening Strategic Leadership in Cell and Gene Therapy Policy and Market Access

Charlotte Ivancic brings more than 18 years of experience on Capitol Hill, where she played a key role in shaping healthcare legislation and advising senior leadership in both the U.S. Senate and House of Representatives. Her…

Leukopak vs PBMC vs Whole Blood: What’s the Difference and Which One Do You Need?

By camerontucker | May 14, 2026 | Comments Off on Leukopak vs PBMC vs Whole Blood: What’s the Difference and Which One Do You Need?

Leukopak vs PBMC vs Whole Blood: What’s the Difference and Which One Do You Need? Cell therapy, immunology, and translational research programs all rely on high quality human blood derived materials. But one of the most…

T Cell Activation in Cell Therapy: Why T Cell Activation Fails Without the Right Starting Material

By camerontucker | April 17, 2026 | Comments Off on T Cell Activation in Cell Therapy: Why T Cell Activation Fails Without the Right Starting Material

Introduction T cell activation is a foundational step in cell and gene therapy workflows, particularly in CAR T and other adoptive cell therapies. While much attention is placed on genetic engineering and manufacturing scale, activation is…

Why CGT Global Is Positioned to Support the Next Wave of Cell and Gene Therapies

By camerontucker | March 5, 2026 | Comments Off on Why CGT Global Is Positioned to Support the Next Wave of Cell and Gene Therapies

Cell and gene therapy companies rely on several critical pieces of infrastructure to move therapies from development to clinical trials and ultimately to patient treatment. These include reliable sources of GMP compatible starting material,…